Drugs.com Clinical Trial ResultsOriginal article
Abbisko Therapeutics Announces Positive Preliminary Phase 2 Results with Lavengratinib (ABSK061) for the Treatment of Achondroplasia
Phase 2positiveLavengratinibPositive
AI Analysis
Summary
Abbisko Therapeutics announced positive preliminary Phase 2 efficacy results for lavengratinib (ABSK061) in achondroplasia treatment. The data represents a significant milestone for the company's rare disease program.
Clinical Trial Data
Phase
Phase 2
Primary Endpoint
Met
Outcome Details
Positive preliminary efficacy results from Phase II clinical study
Importance:7/10
Sentiment:
0.80
Phase 2 dataRare diseasePositive resultsLavengratinibAchondroplasia
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on September 20, 2026 11:09 PM